ESR1 and breast carcinoma: Inhibition of PTEN activity has been associated with resistance to chemotherapeutic drugs, hypersensitivity to the mTORC1 inhibitor rapamycin as well as hormonal based therapies [199,200] Inhibition of PTEN expression by shRNA resulted in three ERalpha+ breast cancer cell lines that were able to grow in the absence of hormone.